Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Ventana Medical Systems, Inc.

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Ventana Medical Systems, Inc.

Regulatory records
8
Linked recall entries
1
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 8 FDA records to the applicant name Ventana Medical Systems, Inc.. 7 entries are PMA supplements. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Jul 31, 2025 to Aug 25, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code MVC appears in 3 of the 8 linked filings. The collection spans 3 FDA product codes and 3 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P190031, with 3 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.

Applicant mailing address recorded by FDA: 1910 E. Innovation Park Dr., Tucson, AZ, 85755. Recorded on P990081/S060, decision dated Aug 25, 2026.

Changes described in PMA records

P990081/S060: PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody

FDA’s recorded scope: Approval for the PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody as a companion diagnostic (CDx) for identifying patients with gastroesophageal adenocarcinoma (gastric, gastroesophageal junction, and esophageal adenocarcinoma) who may be eligible for treatment with ZIIHERA (zanidatamab).

Aug 25, 2026 · Panel Track

P190031/S016: VENTANA HER2 Dual ISH DNA Probe Cocktail

FDA’s recorded scope: Approval of VENTANA HER2 Dual ISH DNA Probe Cocktail to add the indication for use as a companion diagnostic (CDx) for identifying patients with gastroesophageal adenocarcinoma (GEA; gastric, gastroesophageal junction and esophageal adenocarcinoma) who many benefit from treatment with ZIIHERA (zanidatamab).

Aug 25, 2026 · Panel Track

P190031/S015: HER2 Dual ISH DNA Probe Cocktail

FDA’s recorded scope: Approval to include HER2 Dual ISH DNA Probe Cocktail as a companion diagnostic indication for the determination of HER2 gene amplification status in patients with breast cancer who may benefit from treatment with ENHERTU (fam-trastuzumab deruxtecan-nxki).

May 15, 2026 · Normal 180 Day Track

P990081/S058: PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody

FDA’s recorded scope: Approval to include the PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody (PATHWAY anti-HER2 (4B5) antibody) as a companion diagnostic indication for the detection of HER2 antigen in patients with breast cancer who may benefit from treatment with ENHERTU (fam-trastuzumab deruxtecan-nxki).

May 15, 2026 · Normal 180 Day Track

P990081/S059: PATHWAY anti- HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody

FDA’s recorded scope: This 180-day supplement is to expand labeling of the PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody assay for use as a companion diagnostic to identify patients with HER2-positive, advanced or metastatic breast cancer who may be eligible for treatment with ENHERTU (fam-trastuzumab deruxtecan-nxki) in combination with PERJETA (pertuzumab) as first-line treatment.

Dec 15, 2025 · Normal 180 Day Track

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

RECALL COVERAGE

Recalls linked to this firm

MedtechLedger links 1 FDA enforcement entry through the recorded recalling firm or an exact submission number published in FDA’s recall data. 1 Class II records are represented. Each row is an enforcement entry; one recall event can cover several product entries. These counts describe this collection and do not measure a manufacturer’s safety record or an injury rate.

Connections use the recorded recalling firm or the submission identifiers shown below. A shared submission connects the records; it does not establish that differently named legal applicants are interchangeable. Use the exact affected models, lots and instructions on each notice.

Source information

Source updated Nov 11, 2026. Retrieved Nov 21, 2026.

Devices & associated records

Source information

Source updated Nov 9, 2026. Retrieved Nov 21, 2026.